

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person * <u>Keller Eric L.</u> (Last) (First) (Middle) <u>1104 WEST BROAD STREET</u> <u>SUITE 1029</u> (Street) <u>FALLS CHURCH</u> <u>VA</u> <u>22046</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>10/08/2026</u>	3. Issuer Name and Ticker or Trading Symbol <u>Retension Pharmaceuticals, Inc.</u> [<u>RTSN</u>] Foreign Trading Symbol	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) ☒ Director 10% Owner ☒ Officer (give title below) Other (specify below) <u>Chief Executive Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) ☒ Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned			
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>402,577</u>	<u>D</u>	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)							
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Stock Option (right to buy)</u>	<u>(1)</u>	<u>09/22/2034</u>	<u>Common Stock</u>	<u>80,516</u>	<u>1.43</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>(2)</u>	<u>10/30/2035</u>	<u>Common Stock</u>	<u>128,825</u>	<u>2.43</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>(3)</u>	<u>04/30/2036</u>	<u>Common Stock</u>	<u>32,207</u>	<u>2.43</u>	<u>D</u>	
<u>Series A Convertible Preferred Stock</u>	<u>(4)</u>	<u>(4)</u>	<u>Common Stock</u>	<u>9,662</u>	<u>(4)</u>	<u>D</u>	
<u>Series B Convertible Preferred Stock</u>	<u>(5)</u>	<u>(5)</u>	<u>Common Stock</u>	<u>31,368</u>	<u>(5)</u>	<u>D</u>	

Explanation of Responses:

1. Granted to the Reporting Person on September 23, 2024. The stock options vest in 1/36 monthly increments, with the first vesting date on December 21, 2023, subject to the Reporting Person's continued service to the Issuer on each vesting date.
2. Granted to the Reporting Person on October 31, 2025. The stock options vest in 1/36 monthly increments, with the first vesting date on September 29, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.
3. Granted to the Reporting Person on May 1, 2026. Twenty-five percent of the stock options vest on the first anniversary of the date of grant, with the remaining options vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.
4. The Series A Convertible Preferred Stock (the "Series A Preferred Stock") is convertible into one share of Common Stock at any time at the option of the holder. The Series A Preferred Stock will automatically convert immediately prior to the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. The Series A Preferred Stock has no expiration date.
5. The Series B Convertible Preferred Stock (the "Series B Preferred Stock") is convertible into one share of Common Stock at any time at the option of the holder. The Series B Preferred Stock will automatically convert immediately prior to the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. The Series B Preferred Stock has no expiration date.

Remarks:

Exhibit 24 - Power of Attorney

/s/ Alex Schwartz,
Attorney-in-Fact

** Signature of Reporting
Person

10/08/2026

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

****** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

**POWER OF ATTORNEY
FOR SECTION 16 REPORTING PURPOSES**

Know all by these presents, that the undersigned hereby constitutes and appoints Alex Schwartz, with full power of substitution, as the undersigned's true and lawful attorney-in-fact to:

1) prepare and execute for and on behalf of the undersigned Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder, and any other forms or reports the undersigned may be required to file in connection with the undersigned's ownership, acquisition, or disposition of securities of Retension Pharmaceuticals, Inc. (the "Company");

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, or other form or report, and timely file such form or report with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing, which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of October 5, 2026.

/s/ Eric Keller

Eric Keller